scispace - formally typeset
Search or ask a question
Topic

European LeukemiaNet

About: European LeukemiaNet is a research topic. Over the lifetime, 121 publications have been published within this topic receiving 14554 citations.


Papers
More filters
Journal ArticleDOI
08 Aug 2013-Blood
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.

1,679 citations

Journal ArticleDOI
TL;DR: Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
Abstract: Purpose To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. Methods

1,255 citations

Journal ArticleDOI
26 Feb 2009-Blood
TL;DR: This review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment.

793 citations


Network Information
Related Topics (5)
Myeloid leukemia
36.2K papers, 979.6K citations
86% related
Hematopoietic stem cell transplantation
24K papers, 673.9K citations
85% related
Myeloid
24.1K papers, 980.7K citations
83% related
Haematopoiesis
35.2K papers, 1.6M citations
83% related
Leukemia
54.5K papers, 1.7M citations
82% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
20218
202012
20194
20188
201712
20169